title: Primary lymphoma of bone: experience of 39 cases at the Tata Memorial Hospital, India.
abstract: Primary lymphoma of bone (PLB) is an uncommon clinical entity and a rare presentation of non-Hodgkin's lymphoma. At the Tata Memorial Hospital, over a period of 10 years from 1976 to 1985, 39 cases with a diagnosis of PLB were seen. Twenty-seven cases completed the prescribed treatment and were evaluable for treatment response. Eight patients (21%) presented in clinical stage I (E), four patients (10%) in stage II (E), and 27 patients (69%) in stage IV (E). All of the evaluable patients except two were treated with combination chemotherapy, which consisted of cyclophosphamide, vincristine, and prednisolone in 18 patients, and seven patients received Adriamycin in addition. The majority of patients received six courses of chemotherapy extending over 8 to 12 months. External radiotherapy was given to all except one patient, who had surgery as local treatment. Five patients had generalised relapse, one of which had in addition a local relapse. Five were resistant to treatment. Overall and disease-free survival by Kaplan-Meier method at 60 months are 66% and 56%, respectively.
authors.affiliation: Department of Radiation Oncology, Tata Memorial Hospital, Parel, Bombay, India.
authors.forename: S S
authors.initials: SS
authors.lastname: Susnerwala
authors.forename: K A
authors.initials: KA
authors.lastname: Dinshaw
authors.forename: S C
authors.initials: SC
authors.lastname: Pande
authors.forename: S K
authors.initials: SK
authors.lastname: Shrivastava
authors.forename: M A
authors.initials: MA
authors.lastname: Gonsalves
authors.forename: S H
authors.initials: SH
authors.lastname: Advani
authors.forename: R
authors.initials: R
authors.lastname: Gopal
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate
chemical_list: D004317:Doxorubicin